The study, published Jan. 27, compared the outcomes among the first 30 COVID-19 lung transplant patients at Northwestern to those of 72 patients who needed a lung transplant for other reasons, such as chronic end-stage lung disease.
None of the COVID-19 patients developed lung rejection and all were alive at the time the JAMA article was written, according to a Feb. 2 news release.
“This study proves lung transplantation is highly effective and successful in critically-ill COVID-19 patients,” said Ankit Bharat, MD, study author and chief of thoracic surgery at Northwestern Medicine. “We were especially surprised to find that patients with COVID-19 did not develop rejection of the lungs after transplant.”
Still, lung transplant procedures are much more difficult and carry more risks for COVID-19 patients, researchers said, adding that transplant centers should be selective when considering who the best candidates for such procedures are.
Northwestern Medicine surgeons in June 2020 completed the nation’s first lung transplant on a COVID-19 patient.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
